Androgen Deprivation Therapy Use among Intermediate Risk Prostate Cancer Patients Undergoing Radiation Therapy across a Statewide Radiation Oncology Quality Consortium

M.P. Dykstra, S.N. Regan, H. Yin, P.W. McLaughlin, T.P. Boike, A.K. Bhatt,E.M. Walker, M. Zaki, D. Kendrick, M. Mislmani, S. Paluch, D.W. Litzenberg, M. Mietzel,V. Narayana,A. Smith,W.C. Jackson, D.K. Heimburger,M. Schipper,R.T. Dess

International journal of radiation oncology, biology, physics（2023）

引用 0|浏览0

暂无评分

摘要

Within a state-wide consortium, intended ADT use for intermediate prostate cancer is most strongly associated with Gleason score, ≥50% positive cores, NCCN unfavorable intermediate risk classification, and adverse features on MRI. Nearly half of men had genomic classifier testing underscoring the importance ongoing trials such as NRG/GU 010.

查看译文

关键词

androgen deprivation therapy use,prostate cancer patients,prostate cancer,radiation therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要